Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Week 36

August 31 – September 6, 2026 · 2 articles

Clinical · Molecular biology

Meningioma methylation profiling as a complement to WHO grading: a single-center experience

Karamani L, Müller W, Braune M, et al.

Neurosurgical focus

This retrospective study assessed the clinical relevance of methylation profiling for meningioma risk stratification in 106 patients. Results indicated that methylation profiling, performed using the MethylationEPIC v1.0 chip, was a significantly superior predictor of tumor progression (r = -0.4, p < 0.001) compared to WHO 2021 grading. Although methylation profiling demonstrated enhanced predictive accuracy, particularly for identifying malignant meningiomas, its immediate clinical utility is constrained by a high rate of unclassified tumors (29%) and a delayed turnaround time for results (median 23 days), which is incompatible with prompt postoperative decision-making. The authors conclude that methylation profiling serves as a valuable complementary tool but cannot currently replace established histopathological assessment.

Clinical

First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis

Wang K, Liu W

Clinical & translational oncology

This study evaluated the cost-effectiveness of selpercatinib as a first-line or second-line treatment compared to chemotherapy alone for advanced RET fusion-positive non-small cell lung cancer (NSCLC) from the perspective of US payers. A partitioned survival model was employed to compare clinical outcomes and costs. The findings indicated that selpercatinib, whether used first-line or second-line, was not deemed cost-effective at the current willingness-to-pay threshold of $150,000 per quality-adjusted life-year (QALY). To achieve cost-effectiveness, a substantial price reduction for selpercatinib (approximately 70-77%) would be required. The study concludes that further real-world evidence is needed to inform clinical and health policy decisions.